Introduction {#Sec1}
============

Medications are prescribed with the intention of benefiting the patient. However, the use of medications can be undesirable and potentially lead to harm. These undesirable effects are known as medication-related problems (MRPs). A MRP is defined as an event involving pharmacotherapy that interferes with the patient experiencing an optimal outcome of medical care \[[@CR1]\]. Medications for patients with kidney disease are specialised and complex. In those with chronic kidney disease (CKD), the relevance of optimal pharmacotherapy management is even more critical, thus putting this group of children at risk of developing MRPs. The National Kidney Foundation/Kidney Dialysis Outcome Quality Indicator (NKF/KDOQI) guideline recommends that a medication review should be performed for children and adolescents at all visits for the prevention of MRPs such as inappropriate doses, inadequate therapeutic monitoring and potentially adverse drug effects on the kidney or disease complications \[[@CR2]\].

Medication-related problems are common in children: recent studies have reported that the incidence in the UK is 39.4 % in hospitalised children \[[@CR3]\] and 2.7 % of children on medications were admitted to the emergency departments in the UK \[[@CR4]\]. However, these studies did not include paediatric renal patients. Current management of MRPs in this group is based on what has been learned from adult studies \[[@CR5]\], which may be unrepresentative of the paediatric population. We have previously reported on the paucity of data on the epidemiology of MRPs in children with kidney disease and suggested further studies for proactive strategies in medication safety \[[@CR5]\]. This current study aimed to determine the characteristics of MRPs and potential risk factors for their occurrence in children with kidney disease at the tertiary renal centres.

Materials and methods {#Sec2}
=====================

Setting and study subjects {#Sec3}
--------------------------

Two observational cohort studies were conducted at the renal unit of the Evelina London Children's Hospital (ELCH) and Great Ormond Street Hospital for Children (GOSH). Study 1 was conducted in an inpatient setting at ELCH and GOSH and study 2 was conducted in the renal outpatient clinics at ELCH. Approval was obtained from the Research Ethics Committee, UK. Both hospitals are two of the largest children's renal centres and provide tertiary care to approximately 40 % of children requiring renal replacement therapy (RRT) in the UK \[[@CR6]\]. The renal units are led by teams of paediatric nephrologists, supported by a team of healthcare professionals including specialist renal nurses, renal pharmacists and nutritionists. The cases seen in both units include all aspects of paediatric renal disease, including RRT.

### Study 1, inpatient setting {#d30e355}

The clinical team in both hospitals conducted daily a full patient review and clinical rounds. Clinical pharmacy practice is established as standard care in the inpatient setting; this enabled the pharmacists to review prescription charts as a standard clinical routine. Prescription chart review was conducted using paper documentation in ELCH and from an electronic prescribing system (ePS) in GOSH.

### Study 2, outpatient clinic setting {#d30e360}

The renal outpatient clinics in ELCH operate daily on weekdays. Patients' clinic notes and medication lists were documented on a multidisciplinary electronic medical record (eMR). Unlike the inpatient setting, clinical pharmacy practice is not part of the standard care and thus, prescription chart review was not routine for all patients attending the clinic.

The inclusion criteria for both studies were the same: all children aged 18 years and younger, who had received at least one long-term (non-acute) medication. Additionally, children who were included in the inpatient study had to have been hospitalised for at least 24 h.

Data collection {#Sec4}
---------------

### Study 1, inpatient study {#d30e370}

Data were collected for hospitalised patients at ELCH and GOSH from 1 December 2011 to 1 September 2012. At each site, one pharmacist was responsible for the detection of MRPs using a structured tool and prospective prescription chart review method during routine clinical practice. Recommendations on the resolution of the MRPs were discussed with the clinical team during clinical rounds; this method has been used in previous paediatric MRP studies \[[@CR3], [@CR4], [@CR7], [@CR8]\].

### Study 2, outpatient clinic study {#d30e387}

Data were collected at ELCH from 18 February to 18 September 2013. As clinical pharmacy practice was not a standard care at the outpatient clinic and in order to ensure the consistency of data, one researcher was responsible for identifying MRPs from the eMR, using a structured approach. In the event that an MRP with potential harm to the patient was identified, the researcher would alert the clinical team.

The two pharmacists who were involved in collecting the data in the inpatient setting had received similar professional training and each had more than 10 years' experience in tertiary paediatric renal pharmacy practice. The researcher is also a qualified pharmacist trained in renal pharmacy, but not working in the capacity of a pharmacist within the Trusts. The pharmacists and the researcher received training on the definition and characteristics of MRPs before initiation of the research. All MRPs were recorded onto a proforma using a standard code and operational definition ([Appendix 1](#Sec22){ref-type="sec"}). All prescribed medications associated with MRPs were classified according to the World Health Organisation Anatomical Therapeutic Chemical (WHO-ATC) system.

All different medications prescribed throughout the patients' hospital stay (in study 1) and all medications listed in the patient's clinic notes (in study 2) were recorded.

Incidence and risk factors {#Sec5}
--------------------------

The incidence of MRPs in the study cohort was defined as the number of patients with at least one MRP identified during prescription chart review, divided by the total number of patients reviewed multiplied by 100. For MRP incidence and risk factor calculations, only the first event of MRP identified during review was considered for investigating the association between MRP incidence and potential risk factors.

Analysis of MRP severity {#Sec6}
------------------------

Similar to previously published paediatric MRP studies \[[@CR3], [@CR9]\] this project adopted a validated severity scoring tool for medication errors \[[@CR10]\]. The MRPs were independently assessed by four health care professionals comprising a paediatric nephrology consultant, paediatric consultant pharmacist, medication safety pharmacist and a specialist renal nurse. The MRPs were assessed in terms of clinical significance, with scores ranging from 0 to 10 using a visual analogue scale, where 0 represented a case with no potential harm and 10 represented a case that would result in death. An MRP was considered minor (unlikely to have any adverse effects) if the score was \< 3, moderate (likely to cause some adverse effects or interfere with therapeutic goals) if the score was between 3 and 7, or severe (likely to cause lasting impairment or death) if the score was \> 7. The mean severity score (μScore) from all assessors was the final score assigned to each MRP.

Classification of medications and MRPs {#Sec7}
--------------------------------------

The medications that were associated with MRPs were classified according to the WHO-ATC system. The identified MRPs were documented in a specified proforma adapted from the Pharmaceutical Care Network Europe (PCNE) MRP Classification Scheme \[[@CR11]\]. The operational definition of the types and contributory factors of MRPs is available in [Appendix 1](#Sec22){ref-type="sec"}.

MRP resolution {#Sec8}
--------------

Prescription review was not standard clinical practice in the outpatient clinic; thus, corrective measures and resolution rates could only feasibly be evaluated for MRPs identified during study 1, in the inpatient setting. A MRP was defined as "solved" on occasions when actions were taken before causing any harm to patients or actions were taken to solve an ongoing MRP.

Statistics {#Sec9}
----------

Data were analysed using the Statistical Package for Social Science (SPSS) version 21 and presented as percentages (%), mean with standard deviation (SD) or median with interquartile range (IQR 1--3) and odds ratios (OR) with 95 % confidence interval (CI). For the descriptive analysis of patient and MRP characteristics, Chi-squared (*χ*^2^), Kruskal--Wallis, Rank and Mann--Whitney tests were used as appropriate. In all statistical tests*p* values of less than 0.05 were considered statistically significant.

Multivariate logistic regression was performed to assess the impact of predictors on the likelihood MRPs would occur among the study population. The regression worked around one binary outcome (at least one MRP identified: yes/no) and six independent variables: age (years), gender, number of medications prescribed (Rx) and types of RRT (dialysis, post-transplant and non-RRT). The variable Rx refers to the number of different medications that were prescribed during the data collection period. Additional independent variables analysed in the inpatient study were length of hospital stay in days (LOS) and types of ward admission (elective or non-elective). Elective admission refers to scheduled admission to the ward for inpatient treatment or procedure. Non-elective admission refers to cases transferred from other wards or hospitals for continuation of care. The factors that were analysed in the regression analyses included those found to be relevant in the literature and of pathophysiological significance \[[@CR3], [@CR12]--[@CR14]\].

Results {#Sec10}
=======

A total of 227 patients fulfilled the inclusion criteria and 267 MRPs were identified (*Inpatient,* n = 127 patients, 203 MRPs (mean 1.2 MRPs per patient (SD 2); *Outpatient,* n = 100 patients, 64 MRPs (mean 0.6 MRPs per patient (SD 1.4)). All MRPs were included for analyses. The incidence of MRPs in the inpatient cohort was 19.2 % higher than the Outpatient cohort (51.2 %, 95 % CI 43.2 -- 60.6 % vs. 32 %, 95 % CI 22.9 -- 41.1 %, p = 0.04). The study results are summarised in Table [1](#Tab1){ref-type="table"}.Table 1Summary of results for study 1 (inpatient setting) and study 2 (outpatient renal clinic)Study 1: inpatient settingStudy 2: outpatient renal clinicNumber of patients recruited127100Gender (male)53.5 %,*n* = 6855 %,*n* = 55Median age (IQR) of children with MRPs5.0 (1.3--11.9)10.3 (5.2--13.8)MRP incidence per patient reviewed (95 % CI)51.2 % (43.2--60.6)32 % (22.9--41.1)Significant risk factor for the occurrence of MRPsThe numbers of medicine prescribed per childNone identifiedTotal MRPs identified (*n* = 227)203 MRPs64 MRPsMRP severity levelMinor 68 %, 138 out of 203Minor 9.4 %, 6 out of 64Moderate 32 %, 65 out of 203Moderate 90.6 %, 58 out of 64Predominant MRPsSub-optimal drug effect 21.7 %, 44 out of 203Sub-optimal drug effect 39.1 %, 25 out of 64MRP resolution rateSolved DRPs 96 %, 195 out of 203Not evaluated*MRP* medication-related problem,*DRP* drug-related problem

Characteristics of the study population {#Sec11}
---------------------------------------

The majority of patients were male. Inpatients were younger than the outpatient cohort (inpatient: median 6.6 years \[IQR 1.8--12.5\]; outpatient: median 9.7 (IQR 5.7--14.2),*p* = \<0.001). Inpatients who developed MRPs, compared with those who did not, had a longer length of hospital stay (median 9 vs 4 days,*p* \< 0.001), were on dialysis or had kidney transplant (*p* = 0.001) and more medications prescribed (*p* \< 0.001; Table [2](#Tab2){ref-type="table"}). Of the 127 inpatients, 6 were diagnosed with acute kidney injury (AKI). Of the 6 AKI cases, 1 was secondary to sepsis and another was due to the use of radio-contrast agent. The remaining 4 cases could not be confirmed to have any association with the use of medications as they had unknown causes.Table 2Patient demographic characteristicsInpatients (*N* = 127)Outpatient clinic (*N* = 100)MRPs^b^No MRPs*p* valueMRPs^b^No MRPs*p* valueGender0.440.76  Male37 (29.1)31 (24.4)17 (17.0)38 (45.0)  Female28 (22.0)31 (24.4)15 (15.0)30 (37.0)Median age5.0 (1.3--11.9)8.1 (2.1--13.2)0.2210.3 (5.2--13.8)9.3 (5.7--14.4)0.85Median length of hospital stay (days)9 (4--20)4 (3--7)\<0.001NANANAType of ward admission0.45NANANA  Elective41 (32.3)35 (27.6)  Non-elective24 (18.9)27 (21.3)Renal replacement therapy0.0010.38  Dialysis20 (15.7)8 (6.3)13 (13.0)22 (22.0)  Kidney transplant18 (14.2)11 (8.7)7 (7.0)12 (12.0)  No RRT27 (21.3)43 (33.9)12 (12.0)34 (34.0)Median number of medicines prescribed per child^a^28 (13--15)10 (7--19)\<0.0015 (3--7)5 (3--7)0.55Data are median (IQR 1--3) or frequency (% of*N*)*RRT* renal replacement therapy, *MRP* medication-related problem^a^Median number of medicines prescribed throughout hospital stay^b^At least one MRP identified during prescription review

Risk factors for MRPs {#Sec12}
---------------------

The number of medications prescribed per child was the single significant predictor for MRPs at the inpatient setting (OR 1.06, 95 % CI 1.02--1.10,*p* = 0.002). The odds ratio of 1.06 indicates that the chance of having an MRP is 6 % higher with every additional medication. There was a trend toward a higher prediction of MRPs in patients on dialysis compared with those not on dialysis, but this finding was not statistically significant. None of the predictors analysed here was statistically significant for the outpatient cohort.

MRP severity assessment {#Sec13}
-----------------------

The 64 MRPs identified from the outpatient clinic scored higher on the severity scale compared with the 203 MRPs identified in the inpatient setting (μScore range: outpatient clinic: 2.1--5.8; inpatient 0.1--6.8).

Medications associated with MRPs {#Sec14}
--------------------------------

The groups of medicines most often associated with MRPs were those used for "alimentary tract and metabolism", "systemic anti-infective" and "blood and blood forming organs" (Table [3](#Tab3){ref-type="table"}). MRPs in inpatients were commonly reported with the use of nystatin 7.9 %, 16 out of 203), paracetamol (7.4 %, 15 out of 203) and ranitidine (5.4 %, 11 out of 203), whereas MRPs in outpatients were associated with prednisolone (15.6 %, 10 out of 64), sodium bicarbonate (9.4 %, 6 out of 64) and alfacalcidol (7.8 %, 5 out of 64).Table 3Medications associated with MRPsWHO ATC codeStudy 1: inpatient\
*n* (% of 203)Study 2: outpatient clinics\
*n* (% of 64)(A) Alimentary tract and metabolism^a^  Nystatin, ranitidine, alfacalcidol, calcium carbonate^b^52 (25.6)12 (18.8)(B) Blood and blood-forming organs^a^  Acetylsalicylic acid, erythropoietin, electrolytes (e.g., sodium bicarbonate/chloride)^b^27 (13.3)15 (23.4)(C) Cardiovascular system  Enalapril, furosemide, nifedipine^b^10 (4.9)2 (3.1)(D) Dermatological  Fusidic acid, gentamicin, mupirocin^b^4 (2)0(G) Genitourinary system and sex hormones  Oxybutinin^b^2 (1)0(H) Systemic hormonal preparations, excluding sex hormones  Steroids-based products (e.g., prednisolone, methylprednisolone), octreotide, levothyroxine^b^15 (7.4)10 (15.6)(J) Anti-infectives for systemic use^a^  Penicillins, cephalosporins, vaccines^b^49 (24.1)11 (17.2)(L) Antineoplastic and immunomodulating agents  Tacrolimus, mycophenolic acid, ciclosporine, cyclophosphamide^b^11 (5.4)10 (15.6)(M) Musculo-skeletal system  Pamidronic acid^b^1 (0.5)0(N) Nervous system  Paracetamol, morphine, codeine23 (11.3)3 (4.7)(P) Antiparasitic products, insecticides and repellents  Levimasole^b^1 (0.5)1 (1.6)(R) Respiratory system  Cyclizine, fluticasone, cetrizine^b^7 (3.4)0(S) Sensory organsDexamethasone and anti-infectives^b^1 (0.5)0(V) Various  Polystyrene sulfonate^b^1 (0.5)0*WHO ATC* World Health Organisation Anatomical Therapeutic Chemical system^a^The predominant groups^b^The most common medicines reported in each group

The types and contributory factors of MRPs {#Sec15}
------------------------------------------

Sub-optimal drug effect was the predominant MRP identified in both clinical settings; however, their contributory factors were distinct. The characteristics of the MRPs are presented in Table [4](#Tab4){ref-type="table"}.Table 4Types of medication-related problems (MRPs) identified in the study cohort by the main and sub-categories^a^MRP characteristicsStudy 1, inpatient settingStudy 2, outpatient clinic*n* (%)*n* (%)Types of MRPsP1.1 No effect of drug treatment3/203(1.5)0/64P1.2 Sub-optimal effect44/203(21.7)25/64(39.1)P1.4 Untreated indication20/203(9.9)1/64(1.6)P2.1 Non-allergic reaction22/203(10.8)11/64(17.2)P2.2 Allergic drug reaction3/203(1.5)1/64(1.6)P2.3 Toxic adverse reaction39/203(19.2)2/64(3.1)P3.1 Unnecessary treatment41/203(20.2)0/64P4.1 Patient dissatisfaction1/203(0.5)0/64P4.2 Drug administration problems30/203(14.8)19/64(29.7)P4.3 Delay in treatment0/2035/64(7.8)Contributory factors for MRPs^b^C1 Inappropriate drug selection72/399(18.0)3/73(4.1)C2 Inappropriate drug form7/399(1.8)0/73C3 Inappropriate drug dosage97/399(24.3)4/73(5.5)C4 Inappropriate treatment duration15/399(3.8)0/73C5 Medication errors181/399(45.4)1/73(1.4)C6 Drug supply problems0/3998/73(11.0)C7 Patient factors1/399(0.3)31/73(42.5)C8 Other factors26/399(6.5)26/73(35.6)^a^The operational definition for the types and contributory factors of MRPs is available in Appendix [1](#Sec22){ref-type="sec"}^b^Full description of the contributory factors for MRPs is available in Appendix [2](#Sec23){ref-type="sec"}.

### Inpatient setting {#Sec16}

The predominant MRPs were "sub-optimal drug effect" (21.7 %, 44 out of 203), "unnecessary treatment" (20.2 %, 41 out of 203) and "toxic adverse reaction" (19.2 %, 39 out of 203). The majority of the MRPs were identified and resolved before they caused any harm (55.1 %, 112 out of 203). Prescribing errors in the selection of medications and doses were the main contributory factors for the occurrence of MRPs. The following are examples of cases:Valganciclovir 400 mg once a day was prescribed post-transplant; the dose should have been optimised to 500 mg according to renal function (μScore 2.8).50 mcg stat dose of intravenous prazosin was prescribed to a neonate, but 500 mcg was administered (μScore 5.5).Intravenous gentamicin for septicaemia was prescribed for a patient with acute renal dysfunction; daily doses of gentamicin were continued for 2 weeks without the serum drug level being monitored (μScore 7.4).

### Outpatient clinic {#Sec17}

The predominant MRPs were "sub-optimal drug effect" (39.1 %, 25 out of 64), "drug administration problems" (29.7 %, 19 out of 64) and "non-allergic adverse drug events" (17.2 %, 11 out of 64). The contributory factors for MRPs were associated with patients' medicine-taking behaviour and other factors (e.g. unwanted side effects and dependency on feeding tubes for the administration of medications). The following are examples of cases:A patient with vesicoureteric reflux was dependent on the enteral feeding tube. The family struggled to administer iron supplement (and other oral medications) as prescribed (μScore 2.1).Activated vitamin D for the prevention of hyperparathyroidism was prescribed to a patient with advanced kidney failure. The family had problems in obtaining a continuous supply in the community setting (μScore 3.9).A patient had on-going proteinuria, but had been non-compliant with treatment for the past 6 months (μScore 5.8).

MRP resolution {#Sec18}
--------------

Of the 203 MRPs identified from the inpatient setting, 96 % (195 out of 203) were resolved as a result of multidisciplinary care. Most MRPs were resolved by changes to the medication selection, doses and dosing frequency. The pharmacists played an important role in providing consultations on medication regimens and 99.5 % of the recommendations (227 out of 228) were accepted by the clinical team.

Discussion {#Sec19}
==========

To our knowledge this is the first study investigating MRPs systematically in children with kidney disease in the UK. We observed that whilst not all predictors for MRPs were significant, our results are particularly important, not only in understanding the characteristics of MRPs in this population, but also in enabling the development of preventive strategies in clinical practice.

It is worth discussing further the differences in the demographic characteristics between study subjects in the inpatient and outpatient setting in the current research. Even though all subjects were children with kidney disease, the majority of those seen at the outpatient clinics were in the pre-dialysis stage. Our study shows that those receiving inpatient treatments require three times the numbers of medications than the outpatient cohort (median 17 vs 5 medications per child). Children receiving inpatient treatment were by definition more ill and this was likely due to more advanced disease or complications of RRT. Many studies in adults with CKD have previously demonstrated that patients at the late stage of CKD and on RRT require more complex pharmacotherapy and are exposed to increased chances of MRPs \[[@CR15], [@CR16]\]. There was an association between the occurrence of MRP and the length of hospital stay; however, further research is required to assess causality.

Interestingly, despite having more serious clinical conditions in hospitalised patients, the majority of MRPs were scored as minor (68 %, 138 out of 203) compared with the MRPs identified at the outpatient clinic in which 90.6 % (58 out of 64) were scored as moderate. The possible reason for this lies in the difference of care between tertiary care centres and the community. Problems in the use of medications occurring in inpatients are "active errors" \[[@CR17]\]. Similar to previous paediatric medication error research \[[@CR7], [@CR8], [@CR18], [@CR19]\] the majority of the "active errors" in the current study were caused by prescribing errors. These errors could rapidly be rectified by the healthcare professionals and were less likely to cause harm as a result of the interventions. As an example, sub-optimal tacrolimus dose in the management of post-kidney transplantation on the ward could be adjusted from post-12-h tacrolimus serum drug levels. Changes to drug regimens are directly monitored and patients receiving inpatient treatment are likely to adhere to the prescribed therapy.

In contrast, drug problems occurring in the community are "latent errors", most of which are caused by exogenous factors that are beyond the control of healthcare professionals \[[@CR20]\]. An example of exogenous factors in the current research was difficulties in obtaining unlicensed and off-label medications from the community.

The types of medications associated with MRPs in our study portrayed the common prescribing pattern in the paediatric population \[[@CR3], [@CR21], [@CR22]\]. However, medicines of the "blood and blood forming agents" are unique to MRPs in renal patients \[[@CR12], [@CR13], [@CR23], [@CR24]\]. The medications that were more often associated with MRPs were also those more often prescribed. It is also important to note that there are limited data available for the safe and effective doses of most medications used in children \[[@CR3], [@CR25]\]. This may contributed to the observed tendency for higher numbers of adverse drug events and other MRPs in this cohort.

It is a challenging task to determine an optimal and safe dose for children with kidney disease owing to their physiology and the altered pharmacokinetic properties of medications \[[@CR21], [@CR26]\]. The management of MRPs should be a shared responsibility of all healthcare providers. The MRP classifications and the MRP screening tool used in the present research could also be integrated into the physician's practice.

Other strategies to reduce the occurrence of MRPs are to integrate medication reconciliation into patients' medicine management program. This program was also recently highlighted for the care of adult renal patients \[[@CR27], [@CR28]\]. In the UK, a survey among paediatric pharmacists found that only 34 % had full medication reconciliation in place \[[@CR29]\]. A policy on medication reconciliation on hospital admission and at discharge, including routine outpatient clinic appointments, minimises discrepancies in the transfer of information \[[@CR3]\].

In the inpatient setting, we found that most MRPs are largely attributed to prescribing errors. Prescribing errors have been reported to be preventable; thus, having continuous awareness programmes on medication safety in paediatrics remains essential in practice \[[@CR8], [@CR29]--[@CR32]\].

This study reported the rate of MRP occurrence in children who attended the renal outpatient clinic as less than one MRP per patient. Nevertheless, the potential harm as a consequence of these MRPs should not be underestimated. The latent effect of MRPs in this patient group has not been studied. We identified cases of poor treatment outcome due to patient non-adherence. An example of these cases that was highlighted earlier involved a patient with glomerulonephritis leading to persistent proteinuria.

Difficulties in obtaining medication supplies and poor understanding about medications among parents and children are among the factors causing low adherence in CKD \[[@CR15], [@CR33]\]. Thus, proper coordination of supplies of medication in the community is also vitally important and should be anticipated when unlicensed and/or off-label medications are prescribed for children. Continuous assessment on changing patients' cognitive behaviour towards medicines and/or specific clinical outcomes is also important to empower patients' involvement in managing their medications \[[@CR15], [@CR32], [@CR34]\]. As caring for children with kidney disease is a life-long commitment, parents/carers would benefit from a support system to facilitate them in the monitoring, prevention and resolution of MRPs.

The strengths of this research lie in using multiple approaches to identifying MRPs, i.e. a prospective chart review in the inpatient setting and a retrospective chart review in the outpatient clinic. We were aware that the characteristics of MRPs identified in both studies reflect the types of methods used. Thus, appropriate measures had been taken to minimise the variability of data that include the use of a structured proforma with a standard operational definition and training to those involved in collecting the data. This research included two main referral centres for paediatric nephrology in London. Thus, the results may not necessarily be generalisable to other countries with different care settings.

Conclusion {#Sec21}
==========

Medication-related problems in children with kidney disease necessitate a comprehensive approach to their identification and resolution. The MRPs in different clinical settings are unique in their characteristics and levels of severity. Investment in preventive strategies and extending the support from the health care setting into the community are invaluable for optimising pharmacotherapy.

Appendix 1 {#Sec22}
==========

Table 5Coding system for the types and contributory factors of medication-related problems (MRPs) and the operational definition of the modified Pharmaceutical Care Network (PCNE) MRP classification version 6.2Main category: types of MRPsCodesSub-categoriesOperational definitionDrug effectP1There is a (potential or manifested) problem with the (lack of) effect of the pharmacotherapyP1.1No effect of treatment/therapy failureThere is neither improvement nor worsening of the patient's symptomsP1.2Sub-optimal drug effectThere is improvement in the patient's symptoms, but not to the intended targetP1.3Wrong effect of drug treatmentNAP1.4Untreated indicationThere is a symptom (or an anticipated symptom) requiring drug therapy that is not treatedAdverse drug eventsP2Patient suffers, or will suffer, from an adverse drug eventP2.1Non-allergic adverse reactionAn unintended pharmacological effect from an adverse drug event not suspected as an allergic reaction (or toxic effect) commonly known to be related to the prescribed drug at doses normally used for the intended indication (e.g. side effects, intolerable intended pharmacological effect, e.g. hypotension from the use of antihypertensive agent)P2.2Allergic drug reactionAn unintended pharmacological effect from an adverse drug event suspected as an allergy reaction or toxicity, commonly known to be related to the prescribed drug at doses normally used for the intended indication (e.g. rash and penicillin)P2.3Toxic adverse reactionAn unintended pharmacological effect related to the drug at doses higher than maximum dose normally used for the intended indication or adverse effect cause by accumulated dosesTreatment costsP3The drug treatment is more expensive than necessaryP3.1Drug treatment more costly than necessaryThere is an alternative drug that is cheaper, but is not being usedP3.2Unnecessary drug treatmentThe drug that is newly (or previously) prescribed is not required (or no longer required)OtherP4Other causes not specified aboveP4.1Patient dissatisfied with therapy despite optimal clinical and economic treatment outcomesSelf-explanatoryP4.2Drug administration problemsDifficulties in administering the appropriate drug at the correct doses to the intended patient (e.g. paracetamol suppository (540 mg) was prescribed, but the preparation available at the dispensary is a 240-mg suppository; incomplete instructions of drug administration; any circumstance that hinders drug administration)P4.3Delay in treatmentSelf-explanatoryDrug selectionC1The cause of the DRP is related to the selection of the drugC1.1Inappropriate drug (including contra-indication)The wrong drug is selected or the selected drug is contraindicated for the patient.Wrong drug is, for example, a patient who is supposed to be on antibiotic A, but is administered antibiotic BContraindicated drug use is, for example, a patient who received a drug to which he had previously experienced an allergy reactionC1.2Inappropriate combination of drugsThe selected drug interacts (or has the potential to interact) with another drug(s), food or deviceC1.3Inappropriate duplication of therapeutic group or active ingredientMore than one drug of the same therapeutic group or active ingredient is used concurrentlyC1.4Indication for drug treatment not noticedThe drug that is indicated to treat a symptom is not used because the existence of the symptom is not noticedC1.5Too many drugs prescribed for an indicationMore than the necessary drugs are used for treating the same symptom(s)C1.6More cost-effective drug availableAn alternative drug that is cheaper and as effective (or more effective) is not usedC1.7Synergistic/preventive drug required and not givenA drug that is required to enhance the existing treatment (synergistic effect) or to prevent the development of another symptom is not usedC1.8New indication for drug treatment presentedThe drug has a new indication that requires a change of dosing regimen (e.g. steroid maintenance dose in post-transplantation and pulse doses in acute rejection)Drug formC2Inappropriate drug formC2.1Inappropriate drug formInappropriate drug form and/or formulationDose selectionC3The cause of the DRP is related to the selection of the dosage scheduleC3.1Drug dose too lowDose is insufficient to achieve the therapeutic outcomeC3.2Drug dose too highDose is more than necessary to achieve the therapeutic outcomeC3.3Dosage regimen not frequent enoughDosing frequency is insufficient to achieve the therapeutic outcomeC3.4Dosage regimen too frequentDosing frequency is more than necessary to achieve the therapeutic outcomeC3.5No therapeutic drug monitoringSerum level for a drug with a narrow therapeutic index, not monitoredC3.6Pharmacokinetic problem requiring dose adjustmentChanges in renal function requiring dose adjustmentC3.7Deterioration/Improvement of disease state requiring dose adjustmentChanges to disease state requiring dose adjustmentC3.8Dose difficult to measurePrescribed dose difficult to measureTreatment durationC4The cause of the DRP is related to the duration of therapyC4.1Treatment duration too shortTreatment duration is shorter than necessaryC4.2Treatment duration too longTreatment duration is longer than necessaryMedication errorsC5Mishaps or accidents during at any stage of drug handling, prescribing, transcribing, dispensing and administeringC5.1Inappropriate timing of administration and/or dosing intervalsError in the process of drug administrationC5.2Drug underused/under-administeredError in the process of drug administrationC5.3Drug overused/over-administeredError in the process of drug administrationC5.4Drug not taken/administered at allError in the process of drug administrationC5.5Wrong drug taken/administeredError in the process of drug administrationC5.6Drug abused (unregulated overuse)Self-explanatoryC5.7Patient unable to use drug/drug form as directedMoved to category patient factor (C7.5)C5.8aPrescribing error in decision makingError in deciding treatmentC5.8bPrescribing error in prescription writingError in writing prescriptionC5.9Dispensing errorError in dispensing the prescribed drugC5.10Dilution errorError in the process of diluting a drug to its prescribed concentrationDrug supplyC6.1Prescribed drug not availablePrescribed drug not available for useC6.2Difficulty in obtaining repeat prescription from the communityThere is a problem in obtaining repeat prescription(s) from the general practitioner (GP) or the community pharmacyPatient factorC7The cause of the DRP can be related to the personality or behaviour of the patientC7.1Patient forgot to use/take drugSelf-explanatoryC7.2Patient used unnecessary drugSelf-explanatoryC7.3Patient took food that interacts with the prescribed drug(s)Self-explanatoryC7.4Patient stored drug inappropriatelySelf-explanatoryC7.5Patient refused to take the drugSelf-explanatoryC7.6Patient unable to use the drugSelf-explanatoryC7.7Patient (parent/carer) forgot to obtain repeat prescription(s) from the communitySelf-explanatoryC7.8Poor understanding of treatment plan and medicationsSelf-explanatoryOthersC8Other causes not specified aboveC8.1Poor medication reconciliationDiscrepancies between the patient's own drugs with those prescribed on admission.Discrepancies between drugs planned to take home and the ones on discharge prescriptionsC8.2Unwanted side effectsKnown undesirable effect of a drug other than the intended therapeutic effectsC8.3Inappropriate drug administration site/routeWrong site and/or route for the prescribed drugC8.4Dependent on enteral feed tubesThe patient is dependent on enteral feeding tubes for the administration of medicinesC8.5Difficulty in obtaining information from the general practitionerSelf-explanatoryC8.6New dose not altered by the general practitionerSelf-explanatory*NA* not applicable
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==========

Table 6Contributory factors for medication-related problems (MRPs) at the inpatient and outpatient renal clinic\*Inpatient (*N* ~1~ = 399)Outpatient (*N* ~2~ = 73)Contributory factors for MRPs*n* (%)*n* (%)C1 Drug selection72(18.0)3(4.1)  C1.7 Synergistic/preventive drug not prescribed20(5.0)1(1.4)  C1.9 No indication13(3.3)--\--  C1.1 Inappropriate drug10(2.5)1(1.4)  C1.3 Inappropriate drug duplication9(2.3)1(1.4)  C1.4 Indication for drug not noticed7(1.8)--\--  C1.5 Too many drugs unnecessarily for the same indication6(1.5)--\--  C1.2 Inappropriate drug combination5(1.3)--\--  C1.6 More cost-effective alternative available1(0.3)--\--  C1.8 New indication1(0.3)--\--C2 Inappropriate drug form7(1.8)--\--C3 Drug dosage97(24.3)4(5.5)  C3.2 Dose too high23(5.8)1(1.4)  C3.1 Dose too low17(4.3)2(2.7)  C3.4 Dosage regimen too frequent15(3.8)--\--  C3.7 Deterioration/improvement of disease state10(2.5)--\--  C3.3 Dosage regimen not frequent enough8(2.0)--\--  C3.6 Pharmacokinetic problem requiring dosage adjustment8(2.0)--\--  C3.5 No therapeutic monitoring3(0.8)--\--  C3.8 Dose difficult to measure13(3.3)--\--C4 Treatment duration15(3.8)--\--  C4.2 Too long13(3.3)--\--  C4.1 Too short2(0.5)--\--C5 Medication errors181(45.4)1(1.4)  C5.8a Prescribing error in decision making104(26.1)1(1.4)  C5.8b Prescribing error in prescription writing72(18.0)--\--  C5.2 Drug over-administered2(0.5)--\--  C5.1 Inappropriate timing of drug administration/dosing intervals2(0.5)--\--  C5.9 Dispensing error1(0.3)--\--C6 Drug supply**----**8(11.0)  C6.2 Problems with the process for obtaining repeat prescriptions from the community-----8(11.0)C7 Patient factors1(0.3)31(42.5)  C7.5 Refused to take medicines1(0.3)6(8.2)  C7.1 Forgot to take the drug----10(13.7)  C7.7 Forgot to ask for refill prescription from community----1(1.4)  C7.8 Poor understanding of treatment plan and medications14(19.2)C8 Other factors26(6.5)26(35.6)  C8.2 Unwanted side effects14(3.5)12(16.4)  C8.1 Poor medication reconciliation12(3.0)--\--  C8.4 Dependent on NG/PEG for medications----8(11.0)  C8.5 Difficult to obtain information from GP----5(6.8)  C8.6 New dose not altered by the GP----1(1.4)*NG* nasogastric,*PEG* percutaneous endoscopic gastrostomy

The authors wish to thank the Ministry of Health Malaysia for funding Norkasihan Ibrahim in this PhD research, Deborah Riddout and Monalis Bagkeris of UCL Institute of Child Health for their statistical advice, the Renal and Pharmacy team of ELCH and GOSH, especially William Thornhill, Susan Patey, Christine Booth, Nikesh Gudka and Iek Leng Cheng for their professional cooperation.

Ethics approval {#d30e1778}
===============

This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki; approved by the National Research Ethics Committee, London, UK (11/LO/0879; 12/LO/0709) and informed consent was given to all subjects before inclusion.
